Dengue Vaccines Market Value Share, Supply Demand, share and Value Chain 2016-2026
Future Market Insights has announced the addition of the “Dengue Vaccines Market: Global Industry Analysis and Opportunity Assessment 2016-2026” report to their offering.
Future Market Insights has announced the addition of the “Dengue Vaccines Market: Global Industry Analysis and Opportunity Assessment 2016-2026” report to their offering.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Global <strong>Dengue</strong><br />
<strong>Vaccines</strong> <strong>Market</strong><br />
<strong>Share</strong>, Global Trends,<br />
Analysis, Research, Report,<br />
Opportunities,<br />
Segmentation <strong>and</strong> Forecast,<br />
<strong>2016</strong>-<strong>2026</strong><br />
Future <strong>Market</strong> Insights<br />
www.futuremarketinsights.com<br />
sales@futuremarketinsights.com
Future <strong>Market</strong> Insights (FMI) is a premier provider of syndicated research reports, custom research reports, <strong>and</strong> consulting<br />
services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,<br />
technology inputs, valuable growth insights, aerial view of the competitive framework, <strong>and</strong> future market trends.<br />
We provide research services at a global as well as regional level; key regions include GCC, ASEAN, <strong>and</strong> BRIC.<br />
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, <strong>and</strong><br />
Retail.<br />
We have a global presence with delivery centers across India specializing in providing global research reports <strong>and</strong> country<br />
research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.<br />
We combine our knowledge <strong>and</strong> learning from every corner of the world to distill it to one thing – the perfect solution for<br />
our client.<br />
Research Capabilities<br />
• Customized Research<br />
• Syndicated Research<br />
• Investment Research<br />
• Social Media Research<br />
Sector Coverage<br />
• Automotive <strong>and</strong> Transportation<br />
• Electronics, Semiconductor, <strong>and</strong> ICT<br />
• Retail <strong>and</strong> Consumer Products<br />
• Industrial Automation <strong>and</strong> Equipment<br />
• Chemicals & Materials<br />
• Food <strong>and</strong> Beverages<br />
• Services <strong>and</strong> Utilities<br />
• Energy, Mining, Oil, <strong>and</strong> Gas<br />
Customized<br />
Research<br />
Syndicated<br />
Research<br />
Investment<br />
Research<br />
Social Media<br />
Research<br />
Subscription Information<br />
For detailed subscription information please contact<br />
Hari. T (Sr. Manager - Global Business Development)<br />
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268<br />
Email: hari.t@futuremarketinsights.com
Report Description<br />
<strong>Dengue</strong> is a mosquito-born flavivirus disease <strong>and</strong> causes dengue fever characterized by<br />
severe headache, skin rash, debilitating muscle, joint pain leaving a feverish feeling. The<br />
dengue virus is also called as ‘breakbone fever’ due to the symptoms it causes. The<br />
symptoms for dengue start appearing in the span of 3-14 days <strong>and</strong> can infect infants,<br />
young children <strong>and</strong> adults. <strong>Dengue</strong> has emerged as one of the critical vector-borne<br />
diseases especially in tropical <strong>and</strong> subtropical regions of the world. The first dengue<br />
vaccine, Dengvaxia (CYD-TDV) developed by Sanofi Pasteur registered in Mexico in<br />
December, 2015. CYD-TDV vaccine is a live recombinant tetravalent dengue vaccine<br />
which was evaluated as a 3 dose series 0/6/12 month schedule in Phase III clinical<br />
studies. There are around five other vaccine c<strong>and</strong>idates under evaluation in clinical trials,<br />
comprising other live-attenuated vaccines, as well as subunit, DNA <strong>and</strong> purified<br />
inactivated vaccine c<strong>and</strong>idates. Along with the developments in dengue vaccines<br />
additional technological approaches, such as virus-vectored <strong>and</strong> VLP-based vaccines, are<br />
held under evaluation in preclinical studies for further advancements.<br />
The development for dengue vaccine had begun by 1929 but was delayed due to the<br />
incomplete knowledge of the diseases. Sanofi Pasture first approved the vaccine for<br />
dengue in 2015 <strong>and</strong> integrated dengue prevention reducing the mortality rate by almost<br />
50%. WHO Strategic Advisory Group of Experts (SAGE) on Immunization reviewed CYD-<br />
TDV in April <strong>2016</strong> <strong>and</strong> recommended countries to introduce the vaccine through its<br />
Global dengue prevention <strong>and</strong> Control Strategy (2012-2020).
Report Description<br />
Request for sample report: http://www.futuremarketinsights.com/reports/sample/repgb-1763<br />
The drivers for dengue vaccine market include growing healthcare concerns, increase in<br />
mortality rate because of dengue fever. And the challenges faced by the scientist in<br />
developing this vaccines were majorly due to the complexity of the dengue virus,<br />
expensive trials <strong>and</strong> time to develop them. After the introduction of Dengvaxia (CYD-<br />
TDV), five additional c<strong>and</strong>idates are I clinical trials. The prices for dengue vaccines are<br />
much higher but due to government intervention the vaccine are sold on discounted<br />
prices in most countries. In March <strong>2016</strong>, Dengvaxia was licensed in Mexico, the<br />
Philippines, Brazil <strong>and</strong> El Salvador for effective prevention against dengue from all four<br />
serotypes which are mostly found in individuals of age 9-45 years living in endemic areas.<br />
According to WHO (World Health Organization) dengue epidemics are being reported<br />
every year from more than 100 endemic countries causing 50-100 million dengue<br />
infections worldwide annually. In the years 2010, 2013 <strong>and</strong> 2015, nearly 2.4 million cases<br />
of dengue had been reported indicating the sharp increase in the number. It was<br />
estimated 500 000 people with severe dengue require hospitalization each year <strong>and</strong> from<br />
them 2.5% of those affected die each year. The dengue vaccine is being produced in in<br />
France in dedicated manufacturing site including a full-scale production capacity of 100<br />
million of vaccine doses annually.
Report Description<br />
In <strong>2016</strong>, Philippines had registered to have the highest incidence of confirmed dengue<br />
among the 10 endemic countries which had participated in clinical efficacy studies for the<br />
vaccine. In April <strong>2016</strong>, the first public dengue immunization program was started in the<br />
Philippines. The major launch event which was hosted by the Department of Health<br />
(DoH) of the Philippines, which lists the details about the country’s plan of vaccinating<br />
about 1 million public school children <strong>and</strong> was <strong>share</strong>d with the international <strong>and</strong> national<br />
press during the event. Where in February, Sanofi Pasteur’s dengue vaccine was firstly<br />
made available for the private sector vaccination in the Philippines<br />
Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1763<br />
In the history of global burden of diseases, dengue which bears about 70% of it had an<br />
optimism after the first approval of the vaccine. Due to the developments in the recent<br />
years, pharmaceutical companies have started making effort in developing dengue<br />
vaccine <strong>and</strong> have registered their products for clinical trials. Companies such as<br />
GlaxoSmithKline plc, Merck & Co., Inc. <strong>and</strong> Takeda Pharmaceutical Company Ltd. are each<br />
at different stages in developing the vaccines for dengue.
Thank You!<br />
To know more about us, please visit our website:<br />
www.futuremarketinsights.com<br />
For sales queries or new topics email us on:<br />
sales@futuremarketinsights.com<br />
Future <strong>Market</strong> Insights: 616 Corporate Way, Suite 2-9018,<br />
Valley Cottage, NY 10989, United States<br />
T: +1-347-918-3531 | D: +1-845-579-5705